Relay Therapeutics (RLAY) Scheduled to Post Earnings on Wednesday

Relay Therapeutics (NASDAQ:RLAY) will be releasing its earnings data after the market closes on Wednesday, November 6th. Analysts expect Relay Therapeutics to post earnings of ($0.77) per share for the quarter.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same quarter last year, the company posted ($0.81) EPS. On average, analysts expect Relay Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relay Therapeutics Trading Up 0.2 %

RLAY opened at $5.72 on Thursday. The company’s fifty day moving average price is $6.93 and its two-hundred day moving average price is $7.03. Relay Therapeutics has a 1-year low of $5.70 and a 1-year high of $12.14. The company has a market cap of $765.85 million, a price-to-earnings ratio of -2.27 and a beta of 1.64.

Wall Street Analyst Weigh In

Several research firms have weighed in on RLAY. JMP Securities restated a “market outperform” rating and set a $21.00 price objective on shares of Relay Therapeutics in a report on Tuesday, September 17th. HC Wainwright reiterated a “buy” rating and issued a $19.00 target price on shares of Relay Therapeutics in a report on Monday, October 14th. Bank of America increased their target price on shares of Relay Therapeutics from $20.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. Stifel Nicolaus reiterated a “buy” rating and issued a $28.00 target price on shares of Relay Therapeutics in a report on Monday, September 16th. Finally, Barclays increased their target price on shares of Relay Therapeutics from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 10th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Relay Therapeutics has an average rating of “Moderate Buy” and an average target price of $21.11.

Insiders Place Their Bets

In related news, CFO Thomas Catinazzo sold 6,802 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $6.06, for a total transaction of $41,220.12. Following the transaction, the chief financial officer now owns 306,391 shares in the company, valued at $1,856,729.46. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 4.32% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.